Citigroup Reaffirms “Sell” Rating for agilon health (NYSE:AGL)

agilon health (NYSE:AGL)‘s stock had its “sell” rating restated by investment analysts at Citigroup in a research report issued on Tuesday, MarketBeat.com reports. They presently have a $2.50 target price on the stock, down from their previous target price of $7.00. Citigroup’s price objective indicates a potential upside of 1.63% from the stock’s current price.

Several other research analysts also recently weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and set a $8.00 price objective on shares of agilon health in a report on Wednesday, August 7th. Benchmark reissued a “buy” rating and issued a $9.00 price objective on shares of agilon health in a research note on Thursday, August 8th. Evercore ISI dropped their target price on agilon health from $7.00 to $4.00 and set an “in-line” rating on the stock in a report on Tuesday, October 8th. Bank of America downgraded agilon health from a “buy” rating to an “underperform” rating and set a $3.00 price target for the company. in a report on Wednesday, October 2nd. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on agilon health from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, August 9th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.81.

agilon health Price Performance

Shares of NYSE AGL opened at $2.46 on Tuesday. The company has a current ratio of 1.36, a quick ratio of 1.36 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average price is $3.50 and its 200-day moving average price is $5.09. The firm has a market capitalization of $1.01 billion, a P/E ratio of -3.37 and a beta of 0.54. agilon health has a 1-year low of $2.36 and a 1-year high of $18.37.

agilon health (NYSE:AGL) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.56 billion. agilon health had a negative return on equity of 29.91% and a negative net margin of 5.57%. The company’s quarterly revenue was up 38.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) earnings per share. Equities research analysts anticipate that agilon health will post -0.32 earnings per share for the current fiscal year.

Insider Buying and Selling at agilon health

In other agilon health news, CEO Steven Sell bought 20,000 shares of agilon health stock in a transaction dated Thursday, September 12th. The stock was purchased at an average price of $3.36 per share, for a total transaction of $67,200.00. Following the completion of the purchase, the chief executive officer now directly owns 67,590 shares of the company’s stock, valued at approximately $227,102.40. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On agilon health

Several hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in agilon health by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 28,947,798 shares of the company’s stock worth $176,582,000 after purchasing an additional 371,537 shares during the period. Capital International Investors grew its stake in agilon health by 84.7% during the first quarter. Capital International Investors now owns 20,197,932 shares of the company’s stock valued at $123,207,000 after acquiring an additional 9,263,296 shares in the last quarter. AQR Capital Management LLC grew its stake in agilon health by 3,338.5% during the second quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company’s stock valued at $8,871,000 after acquiring an additional 1,316,990 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in agilon health by 18.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,921 shares of the company’s stock worth $7,252,000 after acquiring an additional 174,883 shares during the period. Finally, Susquehanna Fundamental Investments LLC lifted its stake in agilon health by 65.0% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 804,594 shares of the company’s stock worth $5,262,000 after purchasing an additional 316,856 shares in the last quarter.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.